Featured Research

from universities, journals, and other organizations

Chronic inflammation: Slowing down immune system when in overdrive

Date:
February 10, 2014
Source:
Garvan Institute of Medical Research
Summary:
Many people suffer from chronic inflammation because their immune systems overreact to 'self' tissue. Scientists believe that a small molecule known as Interleukin 21 is a promising therapeutic target in such cases.

Many people suffer from chronic inflammation because their immune systems overreact to 'self' tissue. Sydney scientists believe that a small molecule known as Interleukin 21 is a promising therapeutic target in such cases.

Interleukin 21 (IL-21) is one of a group of chemical messengers known as 'cytokines', which affect the behavior of immune cells. IL-21 is already well known to play an important role in autoimmune diseases such as Sjφgren's syndrome and type 1 diabetes.

The current study shows how much IL-21 contributes to inflammation. It also shows how important it is to remove IL-21 to reduce inflammation, even where there are other severe immune defects present.

Undertaken at Sydney's Garvan Institute of Medical Research, researchers used mice genetically deficient in another cytokine (IL-2), a well-established mouse model of autoimmunity. In some mice, the IL-21 cell surface receptor was also genetically removed. In these mice, inflammatory disease was much less severe, demonstrating that IL-21 contributes to fatal inflammatory disease.

Immunologists Associate Professor Cecile King and Dr Alexis Vogelzang, in collaboration with bioinformatics experts Drs Marcel Dinger and Brian Gloss, combined cellular analysis and RNA sequencing to compare genes expressed in the disease model with those expressed in healthy immune cells. The study confirmed that IL-21 is one of the most highly expressed genes in autoimmune disease.

The findings are published in the Journal of Immunology, now online.

"RNA sequencing is an unbiased way of determining differential expression of genes, and this data revealed the proinflammatory gene signature of autoimmune disease and confirmed the extent to which IL-21 is elevated in the absence of IL-2," said Associate Professor King.

"When you remove the IL-2 gene, another group of very calming immune cells known as 'T regulatory cells' also disappear -- because T regulatory cells express high levels of the IL-2 receptor and are IL-2 dependent. Without T regulatory cells, the immune system goes haywire and the body starts attacking itself."

"Under these conditions, IL-21 kicks in and make things much worse."

"When IL-21 is blocked, the huge inflammatory response is greatly subdued, although not entirely eliminated."

"There are many people with chronic inflammation caused by defective T cell regulation, and this research suggests that blocking IL-21 with drugs might help them."


Story Source:

The above story is based on materials provided by Garvan Institute of Medical Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. Vogelzang, H. M. McGuire, S. M. Liu, B. Gloss, K. Mercado, P. Earls, M. E. Dinger, M. Batten, J. Sprent, C. King. IL-21 Contributes to Fatal Inflammatory Disease in the Absence of Foxp3 T Regulatory Cells. The Journal of Immunology, 2014; 192 (4): 1404 DOI: 10.4049/%u200Bjimmunol.1302285

Cite This Page:

Garvan Institute of Medical Research. "Chronic inflammation: Slowing down immune system when in overdrive." ScienceDaily. ScienceDaily, 10 February 2014. <www.sciencedaily.com/releases/2014/02/140210095406.htm>.
Garvan Institute of Medical Research. (2014, February 10). Chronic inflammation: Slowing down immune system when in overdrive. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/02/140210095406.htm
Garvan Institute of Medical Research. "Chronic inflammation: Slowing down immune system when in overdrive." ScienceDaily. www.sciencedaily.com/releases/2014/02/140210095406.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins